These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36716576)

  • 1. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
    Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
    Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
    Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
    Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
    Derfuss T; Bermel R; Lin CJ; Hauser SL; Kappos L; Vollmer T; Comi G; Giovannoni G; Hartung HP; Weber MS; Wang J; Jessop N; Chognot C; Craveiro L; Bar-Or A
    Ther Adv Neurol Disord; 2024; 17():17562864241277736. PubMed ID: 39399100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
    Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
    Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
    Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
    Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    Spierer R; Lavi I; Bloch S; Mazar M; Golan D
    J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
    Capuano R; Prosperini L; Altieri M; Lorefice L; Fantozzi R; Cavalla P; Guaschino C; Radaelli M; Cordioli C; Nociti V; Boffa L; Ragonese P; Di Gregorio M; Pinardi F; Torri Clerici V; De Luca G; Gajofatto A; Paolicelli D; Tortorella C; Gasperini C; Solaro C; Cocco E; Bisecco A; Gallo A
    Mult Scler; 2023 Jun; 29(7):856-865. PubMed ID: 37165941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
    Naghavi S; Kavosh A; Adibi I; Shaygannejad V; Arabi S; Rahimi M; Mazaheri S; Ashtari F
    Mult Scler Relat Disord; 2022 Jan; 57():103335. PubMed ID: 35158427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
    Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
    Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pandemic change the ocrelizumab therapy approach? Yes. - Single center ocrelizumab experience.
    Tezer DÇ; Dogan IG; Atmaca MC; Atmaca MM; Demir S
    Ideggyogy Sz; 2022 Nov; 75(11-12):411-417. PubMed ID: 36541145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.